Personalized Treatment Plan for Relapsed or Resistant AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML (acute myeloid leukemia) that has returned or stopped responding to prior treatments
- You are at least 18 years old and in reasonably good overall health (able to carry out light activities)
- Your doctors believe you will likely survive at least 100 days
- You can provide a bone marrow sample or blood sample with enough leukemia cells for testing
- You have recovered from serious side effects of previous cancer treatments
- You are willing to consent to the study and allow use of your tumor tissue samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
This study uses a geriatric assessment to choose the best treatment for people aged 60 and older with acute myeloid leukemia (AML). The goal is to tailor therapy based on your overall health and function.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.